SDC1 and Miyoshi myopathy: Using the in vivo model of 5TMM, Van Valckenborgh et al. (93) have clearly demonstrated that both CD138+ and CD138- MM populations indeed have similar clonogenic capacity and are tumor-initiating in vivo (93).